A short-term clinical study on the effect of purified angiogenic and growth factors from human term placenta in the treatment of chronic varicose ulcers was carried out in 18 patients. Patients were randomly allocated to receive a maximum of two dressings containing or not containing these factors. The amount of granulation and epithelial tissue was clinically estimated 48 hours after each application. Patients treated with placental angiogenic and growth factors showed increased granulation and epithelial tissue. These results indicate that placental factors may be used for acceleration of wound healing.
Introduction
Previous studies have demonstrated that application of human amnion membranes for the treatment of chronic venous ulcers caused the formation of a profusely vascular granulation tissuel-". The use of amnion membranes, however, demands certain laboratory procedures which fall outside routine activities of a hospital. Incorporation of placenta angiogenic and growth factors (PGFs) in a hydrocolloid membrane carrier, that replaces the amnion membrane itself, affords a convenient way for local application of these factors". A short-term, double-blind initial clinical trial of PGFs incorporated in Geliperm was designed to study the effect of these factors on the granulation of chronic varicose ulcers.
Patients and methods
Approval for this trial was obtained from the Hospital Ethical Committee. Patients, admitted via outpatient referrals, agreed to inclusion in a controlled study, and understood they might not be treated with PGFs. All patients, however, would receive adequate treatment, including surgery and skin grafts, following these studies. Patients with evidence of arteriopathy or aetiology other than venous origin, and patients less than 40 years old and more than 85 years old were excluded from the trial.
Preparation of dressings
PGFs from human term placenta were purified by chromatography methodsv', and dressings prepared as previously described", Briefly, pieces of Gelipermdry, a gel dressing made of 1% agar and 3.5% crosslinked polyacrylamide (Geistlich, Wolhunsen, Switzerland), were cut to appropriate size and placed in a sterile dish. Solution of PGFs in buffered saline was evenly dispensed over the gel at a ratio 26 p.g protein/em/ gel, and maintained at room temperature (22°C) for 2 hours to allow PGF incorporation. Control dressings were prepared in a similar way with buffered saline devoid of PGFs.
Protocol
Patients were randomly allocated to receive Geliperm dressings with or without PGFs. Details of the randomization were not disclosed to the clinical team. Initial ulcer cleansing was carried out with halfstrength Eusol followed by Ringer's solution wash and daily dressing with Jelonet, Aserbine or a combination of the two until clean and free of pathogens. Geliperm dressing (with or without PGFs) was then applied and left for 48 hours. Application was repeated if no change had occurred in the ulcer bed. After two applications any ulcer that had still not formed sufficient granulation tissue for skin graft was treated with Jelonetbased dressings until ready for surgery. Procedures following Geliperm dressings were out of the scope of the present studies. Amount of granulation was estimated by visual observation of the ulcer and 35 rom colour photographs taken under standard conditions, and graded as follows: 1, amount of granulation insufficient to allow skin graft; 2, amount of granulation adequate for skin graft; and 3, overgranulation. Initial epithelialization was also recorded. Clinical evaluation was carried out by the same member of the clinical team throughout the duration of the studies. Table 1 summarizes the main clinical details and results obtained. Most patients had a history of deep venous thrombosis and treatment by vein injection and sclerotherapy or ligation and stripping followed by skin grafts. More females than males entered the trial (ratio 2.6 : 1). Randomization procedures allocated 11 patients to receive PGF-Geliperm dressings (experimental group) and 7 patients to receive saline-Geliperm dressings (control group) Mean age (±standard deviation) was 63.73±13.78 years in the experimental group, and 7L57±8.28 years in the control group. Mean ulcer duration was 11.64±7.35 years in the experimental group, and 24.57±15.34 years in the control group. All patients but one (patient number 3) in the experimental group showed increased granulation and initial epithelialization after one PGF-Geliperm dressing, except patient number 11 who needed two applications. None of the patients in the control group showed any change in granulation or epithelialization even after two saline-Geliperm dressings, except patient number 12 presenting a marginal increase in granulation without initial epi thelialization.
Results

Discussion
Higher incidence of ulcers in females has been found in the past-, and this was not considered unusual. Age was not significantly different between experimental and control groups. Randomization Journal of the Royal Society of Medicine Volume 82 October 1989 599 The present studies were designed to find trends on the effect of PGFs in the treatment of chronic ulceration. Results obtained indicate that purified PGFs accelerate the formation of granulation and epithelialization in chronic venous ulcers. Further studies, however, will be needed to find out optimum dose and frequency of application. The search for different combinations of growth factors that would speed wound healing have, so far, been confined to the most well known and characterized growth factors, epidermal growth factor, fibroblast growth factor, platelet derived growth factor, transforming growth factors". Results of the present studies suggest that PGFs, a family of angiogenic peptides with different molecular characteristics than those proteins", may offer a unique combination of growth factors for acceleration and modulation of wound healing.
